FIBRINOGEN, 4 x 2 mL

PRINCIPLE

The fi brinogen determination by clotting time is based on the method originally described by Clauss. In the presence of an excess of thrombin, the fi brinogen is transformed into fi brin and the time to clot formation is inverselly proportional to the concentration of fi brinogen present in the plasma sample.The QCA Thrombin reagent placed in contact with the plasma of the patient, acts on the fi brinogen to be converted into fi brin. This fi brin polymerizes to form a dense network which contributes to the clot formation. The training time can be measured manually or automatically.

DIAGNOSTIC USE

Fibrinogen is a plasma glycoprotein which is involved in the coagulation processes.Fibrinogen increases in infl ammatory processes and tissue diseases (infarction, leukaemia and lupus). Fibrinogen decreases in severe hepatic diseases.Single test result could not be used to make a clinical diagnosis. It should integrate clinical and laboratory data.